KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Accumulated Expenses for 8 consecutive years, with $739.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 18.43% year-over-year to $739.0 million, compared with a TTM value of $739.0 million through Dec 2025, up 18.43%, and an annual FY2025 reading of $739.0 million, up 18.43% over the prior year.
  • Accumulated Expenses was $739.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $561.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $739.0 million in Q4 2025 and bottomed at $432.0 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $533.6 million, with a median of $518.5 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses dropped 17.81% in 2021, then rose 18.43% in 2025.
  • Year by year, Accumulated Expenses stood at $563.0 million in 2021, then grew by 0.53% to $566.0 million in 2022, then rose by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for TEVA at $739.0 million in Q4 2025, $561.0 million in Q3 2025, and $481.0 million in Q2 2025.